Clinical Trial

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

Study acronym: 1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in postoperative adjuvant therapy for HER2-positive upper tract urothelial carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-15; most recent amendment 2025-01-20.
Trial Details
NCT Number NCT05917158
Lead Sponsor Jinling Hospital, China
Conditions Carcinoma, Upper Tract Urothelial Carcinoma, UTUC
Enrollment 30 participants
Start Date 2022-11-23
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-22